Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway

Chaiyawat,Parunya; Sungngam,Patsadakorn; Teeyakasem,Pimpisa; Sirikaew,Nutnicha; Klangjorhor,Jeerawan; Settakorn,Jongkolnee; Diskul‑Na‑Ayudthaya,Penchatr; Chokchaichamnankit,Daranee; Srisomsap,Chantragan; Svasti,Jisnuson; Pruksakorn,Dumnoensun

doi:10.3892/ijo.2019.4737

Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway

Authors:
- Parunya Chaiyawat
- Patsadakorn Sungngam
- Pimpisa Teeyakasem
- Nutnicha Sirikaew
- Jeerawan Klangjorhor
- Jongkolnee Settakorn
- Penchatr Diskul‑Na‑Ayudthaya
- Daranee Chokchaichamnankit
- Chantragan Srisomsap
- Jisnuson Svasti
- Dumnoensun Pruksakorn
View Affiliations

Affiliations: Musculoskeletal Science and Translational Research Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand, Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand, Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok 10210, Thailand
Published online on: February 28, 2019 https://doi.org/10.3892/ijo.2019.4737
Pages: 1704-1718
Copyright: © Chaiyawat et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncogenic drivers of osteosarcoma remain controversial due to the complexity of the genomic background of the disease. There are limited novel therapeutic options, and the survival rate of patients with osteosarcoma has not improved in decades. Genomic instability leads to complexity in various pathways, which is potentially revealed at the protein level. Therefore, the present study aimed to identify the mechanisms involved in the oncogenesis of osteosarcoma using proteomics and bioinformatics tools. As clinical specimens from patients are the most relevant disease‑related source, expression patterns of proteins in osteosarcoma tissues were compared with soft tissue callus from donors containing high numbers of osteoblastic cells. Two‑dimensional electrophoresis and liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) successfully identified 33 differentially expressed proteins in the osteosarcoma tissues compared with the soft tissue callus. Among these proteins, 29 proteins were significantly upregulated in osteosarcoma. A functionally grouped network of the overexpressed proteins, that was created using the ClueGo and CluePedia applications, demonstrated that the unfolded protein response (UPR) pathway was activated mainly through the activating transcription factor 6 arm in osteosarcoma. The results of proteomics analysis were confirmed by elevated expression of UPR‑related chaperone proteins, including 78 kDa glucose‑related protein (GRP78), endoplasmin, calreticulin and prelamin‑A/C, in the patient‑derived primary cells and osteosarcoma cell lines. Furthermore, the expression of GRP78, a master regulator of the UPR, was enhanced in the osteosarcoma tissues of patients that were resistant to double regimen of doxorubicin and a platinum‑based drug. The findings of the present study suggest that targeting the UPR pathway may be promising for the treatment of osteosarcoma.

View Figures

View References

1	Settakorn J, Lekawanvijit S, Arpornchayanon O, Rangdaeng S, Vanitanakom P, Kongkarnka S, Cheepsattayakorn R, Ya-In C and Thorner PS: Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. J Med Assoc Thai. 89:780–787. 2006.PubMed/NCBI
2	Friebele JC, Peck J, Pan X, Abdel-Rasoul M and Mayerson JL: Osteosarcoma: A meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 44:547–553. 2015.
3	Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, et al: EURAMOS collaborators: EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann Oncol. 26:407–414. 2015. View Article : Google Scholar
4	Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project: Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
5	Botter SM, Neri D and Fuchs B: Recent advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chaiyawat P, Pruksakorn D, Phanphaisarn A, Teeyakasem P, Klangjorhor J and Settakorn J: Expression patterns of class I histone deacetylases in osteosarcoma: A novel prognostic marker with potential therapeutic implications. Mod Pathol. 31:264–274. 2018. View Article : Google Scholar :
7	Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z and Huang Y: Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Onco Targets Ther. 9:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
8	Watanabe K, Okamoto K and Yonehara S: Sensitization of osteo-sarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12:10–18. 2005. View Article : Google Scholar
9	Rao-Bindal K, Koshkina NV, Stewart J and Kleinerman ES: The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets. 13:411–422. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES and Lee DA: The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 32:779–792. 2015. View Article : Google Scholar
11	Li Y, Liang Q, Wen YQ, Chen LL, Wang LT, Liu YL, Luo CQ, Liang HZ, Li MT and Li Z: Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet. 198:97–106. 2010. View Article : Google Scholar : PubMed/NCBI
12	Rao UN, Hood BL, Jones-Laughner JM, Sun M and Conrads TP: Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: A proteomics study. Hum Pathol. 44:725–733. 2013. View Article : Google Scholar
13	Einhorn TA and Gerstenfeld LC: Fracture healing: Mechanisms and interventions. Nat Rev Rheumatol. 11:45–54. 2015. View Article : Google Scholar :
14	Murao H, Yamamoto K, Matsuda S and Akiyama H: Periosteal cells are a major source of soft callus in bone fracture. J Bone Miner Metab. 31:390–398. 2013. View Article : Google Scholar : PubMed/NCBI
15	Han W, He W, Yang W, Li J, Yang Z, Lu X, Qin A and Qian Y: The osteogenic potential of human bone callus. Sci Rep. 6:363302016. View Article : Google Scholar : PubMed/NCBI
16	Srisomsap C, Sawangareetrakul P, Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol K, Chokchaichamnankit D, Sirisinha S and Svasti J: Proteomic analysis of cholangiocarcinoma cell line. Proteomics. 4:1135–1144. 2004. View Article : Google Scholar : PubMed/NCBI
17	Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Skrzypczak WF and Mazur A: Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol. 57(Suppl 7): 81–93. 2006.
18	Zhang B, Kirov S and Snoddy J: WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33:W741–W748. 2005. View Article : Google Scholar : PubMed/NCBI
19	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lotia S, Montojo J, Dong Y, Bader GD and Pico AR: Cytoscape app store. Bioinformatic s. 29:1350–1351. 2013. View Article : Google Scholar
21	Pruksakorn D, Teeyakasem P, Klangjorhor J, Chaiyawat P, Settakorn J, Diskul-Na-Ayudthaya P, Chokchaichamnankit D, Pothacharoen P and Srisomsap C: Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma. Int J Oncol. 49:903–912. 2016. View Article : Google Scholar : PubMed/NCBI
22	van Schadewijk A, van't Wout EF, Stolk J and Hiemstra PS: A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones. 17:275–279. 2012. View Article : Google Scholar :
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Schindeler A, McDonald MM, Bokko P and Little DG: Bone remodeling during fracture repair: The cellular picture. Semin Cell Dev Biol. 19:459–466. 2008. View Article : Google Scholar : PubMed/NCBI
25	Mörike M, Schulz M, Nerlich A, Koschnik M, Teller WM, Vetter U and Brenner RE: Expression of osteoblastic markers in cultured human bone and fracture callus cells. J Mol Med (Berl). 73:571–575. 1995. View Article : Google Scholar
26	Luo B and Lee AS: The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 32:805–818. 2013. View Article : Google Scholar
27	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
28	Obacz J, Avril T, Le Reste PJ, Urra H, Quillien V, Hetz C and Chevet E: Endoplasmic reticulum proteostasis in glioblastoma-From molecular mechanisms to therapeutic perspectives. Sci Signal. 10:102017. View Article : Google Scholar
29	Wang M and Kaufman RJ: The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 14:581–597. 2014. View Article : Google Scholar : PubMed/NCBI
30	Dejeans N, Manié S, Hetz C, Bard F, Hupp T, Agostinis P, Samali A and Chevet E: Addicted to secrete - novel concepts and targets in cancer therapy. Trends Mol Med. 20:242–250. 2014. View Article : Google Scholar : PubMed/NCBI
31	Ma Y and Hendershot LM: The role of the unfolded protein response in tumour development: Friend or foe? Nat Rev Cancer. 4:966–977. 2004. View Article : Google Scholar : PubMed/NCBI
32	Hetz C: The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 13:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
33	Dufey E, Urra H and Hetz C: ER proteostasis addiction in cancer biology:. Novel concepts Semin Cancer Biol. 33:40–47. 2015. View Article : Google Scholar
34	Lee AS: Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential. Nat Rev Cancer. 14:263–276. 2014. View Article : Google Scholar : PubMed/NCBI
35	Wang M, Wey S, Zhang Y, Ye R and Lee AS: Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal. 11:2307–2316. 2009. View Article : Google Scholar : PubMed/NCBI
36	Chang SC, Erwin AE and Lee AS: Glucose-regulated protein (GRP94 and GRP78) genes share common regulatory domains and are coordinately regulated by common trans-acting factors. Mol Cell Biol. 9:2153–2162. 1989. View Article : Google Scholar : PubMed/NCBI
37	Yamamoto K, Sato T, Matsui T, Sato M, Okada T, Yoshida H, Harada A and Mori K: Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell. 13:365–376. 2007. View Article : Google Scholar : PubMed/NCBI
38	Yoshida H, Matsui T, Yamamoto A, Okada T and Mori K: XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 107:881–891. 2001. View Article : Google Scholar
39	Luo J, Xia Y, Luo J, Li J, Zhang C, Zhang H, Ma T, Yang L and Kong L: GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma. Cancer Lett. 410:112–123. 2017. View Article : Google Scholar : PubMed/NCBI
40	Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, Yoshida H, Mori K and Kaufman RJ: IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 16:452–466. 2002. View Article : Google Scholar : PubMed/NCBI
41	Lee E, Nichols P, Spicer D, Groshen S, Yu MC and Lee AS: GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 66:7849–7853. 2006. View Article : Google Scholar : PubMed/NCBI
42	Mhaidat NM, Alzoubi KH, Almomani N and Khabour OF: Expression of glucose regulated protein 78 (GRP78) determines colorectal cancer response to chemotherapy. Cancer Biomark. 15:197–203. 2015. View Article : Google Scholar
43	Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR and Hill R: Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 15:1043–1052. 2016. View Article : Google Scholar : PubMed/NCBI
44	Li W, Wang W, Dong H, Li Y, Li L, Han L, Han Z, Wang S, Ma D and Wang H: Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. Oncol Rep. 31:2525–2534. 2014. View Article : Google Scholar : PubMed/NCBI
45	Xia YZ, Yang L, Xue GM, Zhang C, Guo C, Yang YW, Li SS, Zhang LY, Guo QL and Kong LY: Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma. Oncotarget. 7:56371–56382. 2016. View Article : Google Scholar : PubMed/NCBI
46	Schewe DM and Aguirre-Ghiso JA: ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci USA. 105:10519–10524. 2008. View Article : Google Scholar : PubMed/NCBI
47	Shapovalov Y, Benavidez D, Zuch D and Eliseev RA: Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer. 127:67–76. 2010. View Article : Google Scholar
48	Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, et al: GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 100:377–384. 2015. View Article : Google Scholar : PubMed/NCBI